FCCC-PENN SPORE in Ovarian Cancer

Fox Chase癌症中心（FCCC）和宾夕法尼亚大学（PENN）卵巢孢子是两个费城NCI癌症中心之间的合作伙伴关系，要求为该孢子的第11至15年提供支持。在过去的9年里，《孢子》项目不断成熟和发展。看今天的《孢子》，新提交的显著区别在于为《孢子》招募了新的、充满活力的领导层，带来了新的想法、技术和机构投资。这种转化重点得益于SPORE项目的成熟，各机构对卵巢癌研究的深度，以及几乎独特的机构资源，这些资源促进了fcc - penn卵巢癌项目的扩展。在新《孢子》中有5个高度转化的项目。项目包括：PI)用于治疗反应预测分类的基因甲基化特征；P2)改善BRCA1/2携带者卵巢癌风险的估计和沟通，优化决策；P3)卵巢癌微RNA治疗策略；P4)通过新的RNAi方法靶向信号网络改善卵巢癌的治疗；卵巢癌的T细胞治疗进展。该计划由三个独立的核心提供支持，包括行政、生物标本和组织采购以及生物统计和生物信息学核心。SPORE也有一个非常有效的职业发展计划和一个发展试点项目计划，该计划已经成功地启动了许多初级研究人员的职业生涯，并在SPORE的前十年中确定了新的项目。2004年至2014年间，对SPORE和联邦通信委员会-宾夕法尼亚大学卵巢癌项目的投资来自于对SPORE的直接投资（620万美元），另外1090万美元用于宾夕法尼亚大学和联邦通信委员会的卵巢癌项目和教职员工。此外，两个NCI癌症中心还提供了额外的1340万美元，用于支持妇科肿瘤临床和研究基础设施的相关但重要的投资。此外，在过去的五年里，美国联邦通信委员会-宾夕法尼亚大学卵巢孢子研究项目产生了超过1000万美元的抵押品和后续赠款，从而使卵巢癌（但非孢子）项目和基础设施的总投资超过4100万美元。

The Fox Chase Cancer Center (FCCC) and the University of Pennsylvania (PENN) Ovarian SPORE is submitted as a partnership between two Philadelphia NCI Cancer Centers requesting support for years 11 through 15 of this SPORE. Over the last 9 years the SPORE program has matured and evolved. Viewing the SPORE today, the notable difference in the new submission has been the recruitment of new and energetic leadership to the SPORE bringing new ideas, technologies, and institutional investment. This translational focus is a benefit of both the SPORE Program's maturity, the depth of research in ovarian cancer at the institutions, as well as nearly unique institutional resources that catalyzed the expansion of the ovarian cancer program at FCCC-PENN. Within the new SPORE are five highly translational Projects. The projects include: PI) Gene Methylation Signatures for Predictive Classification of Response to Therapy; P2) Improving the Estimation and Communication of Ovarian Cancer Risk among BRCA1/2 Carriers to Optimize Decision Making; P3) Therapeutic Micro RNA Strategies for Ovarian Cancer; P4) Targeting Signaling Networks via Novel RNAi Approaches to Improve Therapy for Ovarian Cancer; P5) Advancing T cell Therapy for Ovarian Cancer. The Programs are supported by three separate cores including an Administrative, Biospecimen and Tissue Procurement, and a Biostatistics and Bioinformatics Cores. The SPORE also has a highly effective Career Development Program and a Developmental Pilot Project Program which has been successful at launching the career of many junior investigators and has served to identify new Projects through the first ten years of the SPORE. The investment in the SPORE and the FCCC-PENN Ovarian Cancer Program between 2004 and 2014 comes through direct investments in the SPORE ($6.2 million), with another $10.9 million into the ovarian cancer programs and faculty at PENN and FCCC. In addition, the two NCI Cancer Centers have provided an additional $13.4 million in associated yet important investments supporting the gynecologic oncology clinical and research infrastructure. In addition, over 10 million dollars in collateral and follow on grants have been generated from FCCC-PENN Ovarian SPORE research in the last five years thus bringing the total ovarian cancer (but non-SPORE) investment into the ovarian cancer programs and infrastructure to over 41 million dollars.